News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Novan Therapeutics’s Nitricil™ Technology Shows Efficacy Against Multidrug Resistant Superbugs


8/19/2014 10:10:36 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

DURHAM, N.C.--(BUSINESS WIRE)--Novan Therapeutics, a clinical-stage biotech company focused on advancing nitric oxide therapies, announced today that the Company’s Nitricil™ platform technology has been shown to be efficacious against several of the most multi-drug resistant pathogens plaguing civilian and military health care providers across the globe. The antimicrobial results from two preclinical studies will be presented this evening at the 2014 Military Health System Research Symposium (MHSRS), taking place in Fort Lauderdale, Florida. Among key findings, Novan’s nitric oxide-releasing technology was shown to be effective against Acinetobacter baumannii, a gram-negative bacterium resistant to nearly all antibiotics, including carbapenems (often considered antibiotics of last resort). A. baumannii causes pneumonia, urinary tract infection, and combat- and trauma-related wound infections.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES